To assess its ability to target EGFR-mutant tumors in the brain, we constructed mouse models with HCC827 cells (Exon 19 deletion) implanted ectopically in the brain. PET/CT and PET/MRI imaging were ...

TAVO412 also demonstrated EGFR and cMET receptor degradation in vivo. Mice bearing HCC827 or NCI-H1975 tumors were treated with TAVO412 twice. The tumors were collected 24 h after the second dose. The ...

Tumor ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a promising therapeutic strategy for combating cancers, particularly in cases involving ...

Proteolysis targeting chimera (PROTAC) technology has emerged as a powerful tool in drug discovery that enables targeted protein degradation through a unique bifunctional approach. This review ...

A wealth of research has focused on developing targeted cancer therapies by specifically inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK). However, the outcome of most ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.